Merck insomnia drug reports positive Phase IIb data at SLEEP meeting
This article was originally published in Pharmaceutical Approvals Monthly
Merck's investigational dual orexin receptor antagonist (DORA) was significantly better than placebo at improving overall sleep at one night and at the end of week four in patients with primary insomnia in a Phase IIb study, the company reported at the annual Meeting of the Associated Professional Sleep Societies in San Antonio June 9. Orexin antagonists are thought to block the stimulation of the brain's arousal system in the hypothalamus. In the dose-ranging study, 243 patients were randomized to one of four doses of MK-4305 and 249 to placebo. The co-primary endpoint was improvement in sleep efficiency on night one and at the end of four weeks. Secondary endpoints were improvement in wake after sleep onset and latency to persistent sleep, compared to placebo. Phase III trials examining MK-4305 in elderly and non-elderly insomnia populations are ongoing, and Merck is targeting 2012 for a filing
You may also be interested in...
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.
EU Business Round-Up: Galenica Boosted By Deals, Alliance's Sales Rise, And Beiersdorf Relaunches Wound Care
Latest EU business news: Galenica posts sales up in 2020 thanks to deals; Alliance Pharma's Consumer sales edge up despite COVID-19; and Beiersdorf is relaunching its wound care range with sustainability in mind.